Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8901126
SERIAL NO

13788770

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Substituted imidazo[1,5-a]quinoxalin-4-one compounds of formula (I) described herein exhibit PDE9-inhibitory action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ASTELLAS PHARMA INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kaizawa, Hiroyuki Tokyo, JP 23 584
Kamijo, Kazunori Tokyo, JP 9 135
Seo, Ryushi Tokyo, JP 17 135
Sugita, Mari Tokyo, JP 4 24
Tsuchiya, Kazuyuki Tokyo, JP 15 66
Yamamoto, Hirofumi Tokyo, JP 129 693
Yamamoto, Satoshi Tokyo, JP 490 4079

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 2, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00